Nanjing Vazyme Biotech Co Ltd
688105
Company Profile
Business description
Nanjing Vazyme Biotech Co Ltd is engaged in conducting technological research and product development focusing on functional proteins such as enzymes, antigens, and antibodies, as well as high molecular weight organic materials.
Contact
Kechuang Road
Building D2, Hongfeng Science and Technology Park
Economic and Technological Development Zone
Jiangsu Province
Nanjing210033
CHNT: +86 2585771179
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3,002
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,016.30 | 9.10 | -0.10% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,770.31 | 572.25 | -1.09% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 25,437.00 | 747.73 | -2.86% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,614.12 | 182.88 | -1.33% |
| S&P 500 | 7,580.07 | 140.32 | -1.82% |
| S&P/ASX 200 | 8,898.20 | 9.90 | -0.11% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |